▸ Responsible for mapping the pharmaceutical market in North Greece, recorded an extended network of healthcare professionals by utilizing market research tools and by assessing doctors’ prescribing capabilities to develop partnerships.▸ Actively participated in the creation of relations with medical doctors of various specialties.☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Achievements: ➜ Received distinctions and positive reviews from the CEO and the HR Director of the company, for contribution to the increase of the company’s turnover.➜ Monitored tender announcements of Regional Health Directorates (DYPE), Military Hospitals and Healthcare Institutions.➜ Monitored and administered the approved credit policy towards pharmaceutical wholesalers to help achieve monthly sales targets. ➜ Implemented restructuring of the Sales Departments and optimized processes.➜ Provided coaching to Sales Team and guided them through the Takeda Selling Model principles (visit preparation, identification of the healthcare client’s needs, objections handling, proposals acceptance, closing of sales, visit review).➜ Carried out segmentation of territories, depending on sales team size. ➜ Evaluated KOLs for each area (IFP-In Field Promotion) Pantoprazole (Zurcazol), Alogliptin (Vipidia), Azilsartan (Edarbi). ➜ Maintained a high share in the developing pantoprazole market (Zurcazol).➜ Recruited expert sales teams for the development of the osteoporosis market. ☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Products: ⚐ GASTROENTEROLOGY: ZURCAZOL - CONTROLOC pantoprazole ⚐ NSAID (XEFO Lornoxicam) ⚐ CALCIORAL calcium carbonate ⚐ HEMOSTASIS: Tachosil ⚐ HYPERTENSION: Edarbi - Edarbyclor ⚐ DIABETES: Vipidia -Vipdomet - Incresync – Drugs for the treatment of Type 2 Diabetes (DPP-4 inhibitors

☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Overview:▸ Participated in monthly meetings with the CEO and the Commercial and Marketing Directors in Athens HQ for analyzing results of sales performance, making comparisons to competition and implementing corrective measures on the company’s commercial plan. ▸ Identified, assessed and selected a team of Pharmaceutical Sales Representatives, while being entrusted with the responsibility of the Office’s supervision to ensure its smooth operation.

☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Overview:▸ Promoted primary care portfolio products to physicians of various specialties ☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Achievements:➜ Overall responsibility and successful management of three separate Product Lines with respective Sales Teams. ➜ Achieved annual turnover increase (10%) for all three Lines.➜ Achieved 20% market share for the parathyroid hormone products’ category from the 1st year after the product’s release, 2006. ➜ Achieved and maintained 50% market share for calcium products (Calcioral-Calcioral D3) from the first years after release. ➜ Planned, implemented and managed a support network for patients under Preotact-parathyroid hormone 1-84 treatment. Trained both patients and nurses in the correct use of the pen (After Sales Treatment).➜ Established a monopoly for the hemostatic product Tachosil in public and private healthcare institutes, April 2005. ➜ Organised network for the Management of Committees’ Approvals for High Cost Medicine of the Greek National Organization for Health Care Provision (EOPYY); approval was granted for Preotact-parathyroid hormone 1-84). ☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Primary Care Products:⚐ GASTROENTEROLOGY: ZURCAZOL - CONTROLOC pantoprazole ⚐ NSAID (XEFO Lornoxicam) ⚐ CALCIORAL calcium carbonate ⚐ HEMOSTASIS: Tachosil ⚐ OSTEOPOROSIS: Preotact- parathyroid hormone 1-84 ⚐ RESPIRATORY: C.O.P.D. (Chronic Obstructive Pulmonary Disease) ⚐ DAXAS (Roflumilast) PDE4 inhibitor ⚐ ALVESCO (Ciclesonide) Corticosteroid Bronchodilator

☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Overview:▸ Built a network of doctors for the promotion of Primary Care portfolio products.☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Products:⚐ CONTRAST AGENTS: IMAGOPAQUE - OMNIPAQUE – VISIPAQUE – OMNISAN, for CT - MRI scans (radiologists and urologists).

☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷☷Overview:▸ Built a network of doctors for the promotion of Primary Care portfolio products.